Eflornithine (hydrochloride hydrate)
CAT:
804-HY-B0744B-02
Size:
10 mM / 1 mL
Price:
Ask
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No
Eflornithine (hydrochloride hydrate)
- CAS Number: 96020-91-6
- UNSPSC Description: Eflornithine hydrochloride hydrate (DFMO hydrochloride hydrate) is a specific, irreversible inhibitor of the enzyme ornithine decarboxylase. Eflornithine hydrochloride hydrate is a medication for the treatment of African trypanosomiasis and excessive facial hair growth in women[1].
- Target Antigen: Parasite
- Type: Reference compound
- Related Pathways: Anti-infection
- Applications: Cancer-programmed cell death
- Field of Research: Cancer
- Assay Protocol: https://www.medchemexpress.com/Eflornithine-hydrochloride,-hydrate.html
- Purity: 98.0
- Solubility: H2O : 83.33 mg/mL (ultrasonic)
- Smiles: NC(CCCN)(C(F)F)C(O)=O.[H]Cl.O
- Molecular Weight: 236.64
- References & Citations: [1]Burri C, et al. Eflornithine for the treatment of human African trypanosomiasis. Parasitol Res. 2003 Jun;90 Supp 1:S49-52.|[2]Balfour JA, et al. Topical eflornithine. Am J Clin Dermatol. 2001;2(3):197-201; discussion 202.|[3]Kumar A, et al. A method to improve the efficacy of topical eflornithine hydrochloride cream. Drug Deliv. 2016 Jun;23(5):1495-501.|[4]Lipke DW, et al. Eflornithine alters changes in vascular responsiveness associated with coarctation hypertension. Clin Exp Hypertens. 1997 Apr;19(3):297-312.Front Oncol. 2021 Mar 11;11:636373.|Sci Adv. 2023 May 19;9(20):eade0718.|bioRxiv. 2024 Jan 15.|Cancer Nanotechnol. 2023 May 9.|Commun Biol. 2019 May 8;2:171.|Food Biosci. 2023 Oct, 55, 102970.|JACC Basic Transl Sci. 2022 Aug 3;7(8):820-840.|Nat Commun. 2024 Mar 19;15(1):2461.|Oncotargets Ther. 2020 Nov 17;13:11697-11709.|RSC Adv. 2019, 9, 11026-11037.
- Shipping Conditions: Room Temperature
- Storage Conditions: 4°C (Powder, sealed storage, away from moisture)
- Clinical Information: Launched